R&D Team | Innovation-Driven

Senior Experts Leading · Next-Generation Talent Advancing · R&D and Industrialization Working Together;
Building an Integrated Innovation Team from Scientific Discovery to Industrial Translation

R&D Team | Driving the Future through Innovation

R&D innovation is a core driver of SR BioPharma’s sustainable growth. With a long-standing focus on anti-HPV research and drug development, the company has built an integrated R&D team led by senior scientific experts and supported by a new generation of technical professionals, with capabilities spanning basic research, drug development, process scale-up, industrialization, and quality management. This has created a well-structured, multidisciplinary talent pipeline that combines complementary expertise with continuity across generations.

The team brings together senior scientists with extensive research experience in molecular virology, protein science, molecular pharmacology, and biopharmaceutical R&D. Its scientific leaders have research backgrounds at internationally recognized universities and research institutions, including the Chinese Academy of Sciences, the University of Tokyo, Tokyo University of Agriculture, the U.S. National Institutes of Health (NIH), the University of Cambridge, Northwestern University, George Washington University, and the University of California, San Francisco (UCSF). Their scientific expertise and experience provide sustained leadership for the advancement of the company’s core anti-HPV technologies and innovative product development.

Under the leadership of senior scientists, SR BioPharma has built a strong next-generation team spanning R&D, process development, scale-up, manufacturing, product registration, and quality management. Together, they form an integrated innovation system that advances scientific discoveries from research to product development and industrialization.

R&D Platforms | Building a High-Standard Foundation

Hainan Provincial Key Laboratory of Protein Engineering and Drug Development, China

Haikou Engineering R&D Center for Life Science Drugs, China

Taizhou R&D Center for Antiviral Drugs

Since 2012, the Group has been continuously recognized as a National High-Tech Enterprise in China. Supported by a professional R&D team and advanced research platforms, the Group has maintained a strong focus on anti-HPV R&D and continued to advance key technological innovations. It has been granted multiple invention patents in China and filed an invention patent application in Singapore in 2025, providing a solid foundation for sustained innovation and development.

30+

Total Research Projects

16+

Patents Granted in China

30++

Research Translation

Pilot-Scale Platform: Accelerating Research Translation and Commercialization

The Group places strong emphasis on pilot-scale capabilities and specialized talent development. Supported by its two pilot-scale platforms in Haikou and Taizhou, the Group has built an integrated system spanning process development, scale-up, quality management, and industrialization, bridging the gap between R&D and commercialization and accelerating the translation of research into commercial products.

R&D Pipeline:
Translating Core Technology into Products

Building on its proprietary Molecularly Targeted Anti-HPV Technology, the Group continues to advance research translation and commercialization, developing and expanding the REBACIN® product portfolio to bring innovative anti-HPV solutions into practical use.

>R&D Pipeline